Description: Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Home Page: biosergen.net
Fogdevreten 2
Solna,
171 65
Sweden
Phone:
46 4 52 08 02 470
Officers
| Name | Title |
|---|---|
| Dr. Peder Moller Andersen | Chief Exec. Officer |
| Mr. Niels Laursen M.B.A. | Chief Financial Officer |
| Ms. Tine Kold Olesen Ph.D. | Chief Operation Officer |
| Mr. Sergey B. Zotchev Ph.D. | Chief Scientific Officer and Member of Scientific Advisory Panel |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.5472 |
| Price-to-Sales TTM: | 16.0537 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |